Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines
Respiratory syncytial virus (RSV) is the main cause of acute respiratory tract infections in infants and it also induces significant disease in the elderly. The clinical course may be severe, especially in high-risk populations (infants and elderly), with a large number of deaths in developing count...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/8/4/672 |
| _version_ | 1797548165924126720 |
|---|---|
| author | Carlotta Biagi Arianna Dondi Sara Scarpini Alessandro Rocca Silvia Vandini Giulia Poletti Marcello Lanari |
| author_facet | Carlotta Biagi Arianna Dondi Sara Scarpini Alessandro Rocca Silvia Vandini Giulia Poletti Marcello Lanari |
| author_sort | Carlotta Biagi |
| collection | DOAJ |
| description | Respiratory syncytial virus (RSV) is the main cause of acute respiratory tract infections in infants and it also induces significant disease in the elderly. The clinical course may be severe, especially in high-risk populations (infants and elderly), with a large number of deaths in developing countries and of intensive care hospitalizations worldwide. To date, prevention strategies against RSV infection is based on hygienic measures and passive immunization with humanized monoclonal antibodies, limited to selected high-risk children due to their high costs. The development of a safe and effective vaccine is a global health need and an important objective of research in this field. A growing number of RSV vaccine candidates in different formats (particle-based vaccines, vector-based vaccines, subunit vaccines and live-attenuated vaccines) are being developed and are now at different stages, many of them already being in the clinical stage. While waiting for commercially available safe and effective vaccines, immune prophylaxis in selected groups of high-risk populations is still mandatory. This review summarizes the state-of-the-art of the RSV vaccine research and its implications for clinical practice, focusing on the characteristics of the vaccines that reached the clinical stage of development. |
| first_indexed | 2024-03-10T14:55:37Z |
| format | Article |
| id | doaj.art-27776b443a2042438cf54f253a0fa6c1 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T14:55:37Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-27776b443a2042438cf54f253a0fa6c12023-11-20T20:36:57ZengMDPI AGVaccines2076-393X2020-11-018467210.3390/vaccines8040672Current State and Challenges in Developing Respiratory Syncytial Virus VaccinesCarlotta Biagi0Arianna Dondi1Sara Scarpini2Alessandro Rocca3Silvia Vandini4Giulia Poletti5Marcello Lanari6Pediatric Emergency Unit, Department of Medical and Surgical Sciences (DIMEC), Sant’Orsola University Hospital, 40138 Bologna, ItalyPediatric Emergency Unit, Department of Medical and Surgical Sciences (DIMEC), Sant’Orsola University Hospital, 40138 Bologna, ItalyPediatric Emergency Unit, Department of Medical and Surgical Sciences (DIMEC), Sant’Orsola University Hospital, 40138 Bologna, ItalyPediatric Emergency Unit, Department of Medical and Surgical Sciences (DIMEC), Sant’Orsola University Hospital, 40138 Bologna, ItalyPediatric and Neonatology Unit, Imola Hospital, 40026 Imola (Bologna), ItalyPediatric Emergency Unit, Department of Medical and Surgical Sciences (DIMEC), Sant’Orsola University Hospital, 40138 Bologna, ItalyPediatric Emergency Unit, Department of Medical and Surgical Sciences (DIMEC), Sant’Orsola University Hospital, 40138 Bologna, ItalyRespiratory syncytial virus (RSV) is the main cause of acute respiratory tract infections in infants and it also induces significant disease in the elderly. The clinical course may be severe, especially in high-risk populations (infants and elderly), with a large number of deaths in developing countries and of intensive care hospitalizations worldwide. To date, prevention strategies against RSV infection is based on hygienic measures and passive immunization with humanized monoclonal antibodies, limited to selected high-risk children due to their high costs. The development of a safe and effective vaccine is a global health need and an important objective of research in this field. A growing number of RSV vaccine candidates in different formats (particle-based vaccines, vector-based vaccines, subunit vaccines and live-attenuated vaccines) are being developed and are now at different stages, many of them already being in the clinical stage. While waiting for commercially available safe and effective vaccines, immune prophylaxis in selected groups of high-risk populations is still mandatory. This review summarizes the state-of-the-art of the RSV vaccine research and its implications for clinical practice, focusing on the characteristics of the vaccines that reached the clinical stage of development.https://www.mdpi.com/2076-393X/8/4/672RSVvaccineprevention |
| spellingShingle | Carlotta Biagi Arianna Dondi Sara Scarpini Alessandro Rocca Silvia Vandini Giulia Poletti Marcello Lanari Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines Vaccines RSV vaccine prevention |
| title | Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines |
| title_full | Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines |
| title_fullStr | Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines |
| title_full_unstemmed | Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines |
| title_short | Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines |
| title_sort | current state and challenges in developing respiratory syncytial virus vaccines |
| topic | RSV vaccine prevention |
| url | https://www.mdpi.com/2076-393X/8/4/672 |
| work_keys_str_mv | AT carlottabiagi currentstateandchallengesindevelopingrespiratorysyncytialvirusvaccines AT ariannadondi currentstateandchallengesindevelopingrespiratorysyncytialvirusvaccines AT sarascarpini currentstateandchallengesindevelopingrespiratorysyncytialvirusvaccines AT alessandrorocca currentstateandchallengesindevelopingrespiratorysyncytialvirusvaccines AT silviavandini currentstateandchallengesindevelopingrespiratorysyncytialvirusvaccines AT giuliapoletti currentstateandchallengesindevelopingrespiratorysyncytialvirusvaccines AT marcellolanari currentstateandchallengesindevelopingrespiratorysyncytialvirusvaccines |